{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-117577","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.225231+00:00","generated_at":"2026-05-16T15:03:39.863744+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protara reports 72% CR for TARA-002 in BCG-Naïve NMIBC; FDA backs registrational path","bullets":["CR at any time 72% (21/29); 69% at 6 months, 50% at 12 months in BCG-Naïve NMIBC.","No Grade 3+ treatment-related adverse events; no discontinuations due to TRAEs.","FDA agreed BCG not required as comparator; intravesical chemo acceptable for registrational trial.","On track for interim BCG-Unresponsive cohort data in Q1 2026; enrollment completion expected 2H 2026.","Re-induction salvaged 80% (4/5) non-responders; all maintained CR at 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-117577","json":"https://secwatch.observer/filing/0001213900-25-117577.json","markdown":"https://secwatch.observer/filing/0001213900-25-117577.md","text":"https://secwatch.observer/filing/0001213900-25-117577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025117577/0001213900-25-117577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025117577/ea0268248-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:03:39.863744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}